Weighing the Benefits and Limitations of CAR T-Cell Therapy and Bispecific Antibodies in ...

Retrieved on: 2024-05-24 20:08:17

Tags for this article:

Orphan drugs

Multiple myeloma

Talquetamab

Idecabtagene vicleucel

Teclistamab

CAR T cell

Ciltacabtagene autoleucel

Lenalidomide

Bispecific monoclonal antibody

Proteasome inhibitor

Monoclonal antibody

B-cell maturation antigen

Click the tags to see associated articles and topics

Weighing the Benefits and Limitations of CAR T-Cell Therapy and Bispecific Antibodies in .... View article details on hiswai:

Excerpt

James Ignatz-Hoover, MD, PhD, discusses the evolving use of CAR T-cell therapies and bispecific antibodies in multiple myeloma ... monoclonal antibody, ...

Article found on: www.onclive.com

View Original Article